Immunization of common marmosets with Epstein-Barr virus (EBV) envelope glycoprotein gp340: Effect on viral shedding following EBV challenge

被引:1
|
作者
Cox, C
Naylor, BA
Mackett, M
Arrand, JR
Griffin, BE
Wedderburn, N [1 ]
机构
[1] Hammersmith Hosp, ICSM, Dept Infect Dis, Div Invest Sci, London W12 0NN, England
[2] Royal Coll Surg England, Dept Pathol, London WC2A 3PN, England
[3] Christie Hosp NHS Trust, Dept Biol Mol, Paterson Inst Canc Res, Manchester M20 4BX, Lancs, England
关键词
EBV vaccine; PCR; buccal fluids;
D O I
10.1002/(SICI)1096-9071(199808)55:4<255::AID-JMV1>3.0.CO;2-#
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Epstein-Barr virus (EBV), the cause of infectious mononucleosis, is involved in the pathogenesis of several human cancers, the highest frequency of association being found in undifferentiated nasopharyngeal carcinoma and endemic Burkitt's lymphoma. The development of animal models in which potential vaccines can be tested is important. EBV infection of the common marmoset, using the M81 strain originally derived from a patient with nasopharyngeal carcinoma, induces a carrier state in this animal. Persistent infection is characterized by the production of antibodies to viral antigens, and the secretion of EBV DNA into buccal fluids. Following immunization with envelope glycoprotein gp340 derived from a bovine papilloma virus expression vector, prior to EBV infection, viral DNA was detected significantly less frequently in the buccal fluids of immunized, than of nonimmunized, infected animals, indicating that although the carrier state had not been abolished, it had been altered. A reduction in virus load was also observed when offspring of seronegative, and on occasion seropositive, parents were immunized neonatally, before EBV challenge. (C) 1998 Wiley-Liss, Inc.
引用
收藏
页码:255 / 261
页数:7
相关论文
共 50 条
  • [41] Development of an Improved Epstein-Barr Virus (EBV) Neutralizing Antibody Assay to Facilitate Development of a Prophylactic gp350-Subunit EBV Vaccine
    Liu, Hui
    Gemmell, Lorraine
    Lin, Rui
    Zuo, Fengrong
    Balfour, Henry H., Jr.
    Woo, Jennifer C.
    Hayes, Gregory M.
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2020, 12
  • [42] Common Epstein-Barr virus (EBV) type-1 variant strains in both malignant and benign EBV-Associated disorders
    Schuster, V
    Ott, G
    Seidenspinner, S
    Kreth, HW
    BLOOD, 1996, 87 (04) : 1579 - 1585
  • [43] Inter-laboratory comparison of Epstein-Barr virus (EBV) viral load (VL) assays.
    Preiksaitis, Jutta K.
    Pang, Xiao-Li
    Fox, Julie D.
    Fenton, Jayne
    Miller, Geraldine
    Caliendo, Angela
    AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 500 - 500
  • [44] Specimen types and reporting units for monitoring Epstein-Barr virus (EBV) viral load in transplant recipients
    Pang, X.
    Preiksaitis, S.
    Preiksaitis, J. K.
    JOURNAL OF CLINICAL VIROLOGY, 2009, 46 : S6 - S6
  • [45] Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)-induced lymphoproliferative disease and lytic viral replication
    Bilger, Andrea
    Plowshay, Julie
    Ma, Shidong
    Nawandar, Dhananjay
    Barlow, Elizabeth A.
    Romero-Masters, James C.
    Bristol, Jillian A.
    Li, Zhe
    Tsai, Ming-Han
    Delecluse, Henri-Jacques
    Kenney, Shannon C.
    ONCOTARGET, 2017, 8 (27) : 44266 - 44280
  • [46] Comparison of commercial ELISA for detection of antibodies to the viral capsid antigen (VCA) of Epstein-Barr virus (EBV).
    Mitchell, JL
    Doyle, CM
    Land, MV
    Devine, PL
    DISEASE MARKERS, 1998, 13 (04) : 245 - 249
  • [47] A common pathogenetic denominator of Epstein-Barr virus (EBV) positive and negative Hodgkin's disease (HD)
    Knecht, H
    McQuain, C
    Berger, C
    Rothenberger, S
    Drexler, HG
    Ouesenberry, PJ
    Odermatt, BF
    EXPERIMENTAL HEMATOLOGY, 1999, 27 (07) : 80 - 80
  • [48] Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection
    Neuhierl, B
    Feederle, R
    Hammerschmidt, W
    Delecluse, HJ
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (23) : 15036 - 15041
  • [49] Immunization with Epstein-Barr Virus Core Fusion Machinery Envelope Proteins Elicit High Titers of Neutralizing Activities and Protect Humanized Mice from Lethal Dose EBV Challenge
    Cui, Xinle
    Cao, Zhouhong
    Ishikawa, Yuriko
    Cui, Sara
    Imadome, Ken-Ichi
    Snapper, Clifford M.
    VACCINES, 2021, 9 (03)
  • [50] INVITRO T-CELL RESPONSES TO A CANDIDATE EPSTEIN-BARR VIRUS-VACCINE - HUMAN CD4+ T-CELL CLONES SPECIFIC FOR THE MAJOR ENVELOPE GLYCOPROTEIN GP340
    ULAETO, D
    WALLACE, L
    MORGAN, A
    MOREIN, B
    RICKINSON, AB
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1988, 18 (11) : 1689 - 1697